S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
NASDAQ:CUE

Cue Biopharma (CUE) Stock Forecast, Price & News

$2.41
+0.05 (+2.12%)
(As of 01:57 PM ET)
Compare
Today's Range
$2.37
$2.56
50-Day Range
$2.23
$4.50
52-Week Range
$2.18
$5.12
Volume
247,628 shs
Average Volume
293,919 shs
Market Capitalization
$108.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

Cue Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
247.2% Upside
$8.33 Price Target
Short Interest
Bearish
5.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
0.08mentions of Cue Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$19,620 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.22) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

339th out of 963 stocks

Pharmaceutical Preparations Industry

144th out of 451 stocks


CUE stock logo

About Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Price History

CUE Stock News Headlines

Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Q2 2023 Cue Biopharma Inc Earnings Call
JMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)
3 Biotech Stocks to Buy as Companies Ink Major Deals
Where Cue Biopharma Stands With Analysts
Cue Biopharma (CUE) Receives a Buy from Piper Sandler
Cue Biopharma to Host Investor Call
Piper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE)
JMP Securities Sticks to Their Buy Rating for Cue Biopharma (CUE)
See More Headlines
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.33
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+247.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-53,010,000.00
Net Margins
-2,899.44%
Pretax Margin
-2,899.39%

Debt

Sales & Book Value

Annual Sales
$1.25 million
Book Value
$1.53 per share

Miscellaneous

Free Float
40,356,000
Market Cap
$107.90 million
Optionable
Not Optionable
Beta
2.02
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel R. Passeri J.D.Mr. Daniel R. Passeri J.D. (Age 62)
    M.Sc., MSc., CEO & Director
    Comp: $985.72k
  • Dr. Anish Suri Ph.D. (Age 49)
    Pres & Chief Scientific Officer
    Comp: $641.98k
  • Ms. Kerri-Ann MillarMs. Kerri-Ann Millar (Age 53)
    Chief Financial Officer
    Comp: $559.03k
  • Dr. Ronald D. Seidel III (Age 47)
    Ph.D., Co-Founder
  • Dr. Rodolfo J. Chaparro (Age 50)
    Co-Founder & Sr. Advisor
  • Dr. Steven C. Almo (Age 62)
    Co-Founder and Chairman of Scientific & Clinical Advisory Board
  • George B. Zavoico Ph.D.
    VP of Investor Relations & Corp. Devel.
  • Mr. Colin G. Sandercock J.D. (Age 66)
    MSE, Sr. VP, Gen. Counsel & Sec.
  • Dr. Matteo Levisetti M.D. (Age 54)
    Chief Medical Officer













CUE Stock - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings
or view top-rated stocks.

What is Cue Biopharma's stock price forecast for 2023?

3 Wall Street analysts have issued 12-month price targets for Cue Biopharma's shares. Their CUE share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 247.2% from the stock's current price.
View analysts price targets for CUE
or view top-rated stocks among Wall Street analysts.

How have CUE shares performed in 2023?

Cue Biopharma's stock was trading at $2.85 at the beginning of 2023. Since then, CUE stock has decreased by 15.8% and is now trading at $2.40.
View the best growth stocks for 2023 here
.

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CUE earnings forecast
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.01. The company earned $1.38 million during the quarter, compared to analyst estimates of $1.21 million. Cue Biopharma had a negative trailing twelve-month return on equity of 95.36% and a negative net margin of 2,899.44%.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.60%), Geode Capital Management LLC (1.62%), State Street Corp (1.45%), Dimensional Fund Advisors LP (1.29%), Silverarc Capital Management LLC (0.90%) and Monaco Asset Management SAM (0.86%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Cameron Gray, Daniel R Passeri, Kenneth Pienta, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends
.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $2.40.

How much money does Cue Biopharma make?

Cue Biopharma (NASDAQ:CUE) has a market capitalization of $107.90 million and generates $1.25 million in revenue each year. The company earns $-53,010,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.cuebiopharma.com. The company can be reached via phone at (617) 949-2680 or via email at ir@cuebio.com.

This page (NASDAQ:CUE) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -